Search Results 3311-3320 of 34307 for oral

1. An Extension Of A Previous Study Evaluating The Use Of SER-109 To Prevent Recurrent Clostridium Difficile Infections - Mayo Clinic

   Antibiotic regimen (for the most recent CDI episode) should be14 days of oral vancomycin (125 mg, q6h) or 10 days of oral fidaxomicin (200 mg, q12h) with ...

2. Thyroid cancer - Doctors and departments - Mayo Clinic

   ... Oral and throat cancer, Laryngeal cancer, Skull base tumor, Oropharyngeal cancer. Show more areas of focus for Daniel J. Ma, M.D. ...

3. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

   ... oral; contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy);; spontaneous ...

4. Floor Of The Mouth Cancer Clinical Trials - Mayo Clinic Research

   This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity ...

5. Mayo Clinic Q and A: Without treatment, RLS can make it difficult to get a good night’s sleep

   Oral iron is generally the first treatment of choice for children with RLS. Certain medications used to treat pain conditions, such as gabapentin, may also ...

6. Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (FLASH) - Mayo Clinic

   * Treatment with systemic corticosteroid use within 8 weeks (oral) ... * For female participants on ethinyl oestradiol containing combined oral contraceptives.

7. Study of Critical Outcomes in Pregnant Patients on Insulin Pump with Type 1 Diabetes - Mayo Clinic

   Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) ...

8. A Study Of The Safety, Pharmacodynamics, Effectiveness, And PK Of TIMP-GLIA In Subjects With Celiac Disease - Mayo Clinic

   ... oral gluten challenge. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

9. Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) - Mayo Clinic

   Written or oral pediatric assent from the subject if deemed capable of ... Progestogen-only hormonal contraception associated with inhibition of ovulation, which ...

10. Regional Lipolysis Insulin Regulation - Mayo Clinic

    All women of childbearing potential will use an appropriate contraceptive method, including barrier method, oral contraceptive medication, contraceptive device ...